Merrimack Pharmaceuticals Inc (MACK) Return on Assets ROA from the first quarter of 2024 to first quarter of 2023 and for the year 2024, Average High and Low, Fundamental Ratios from Mar 31 2024 to Mar 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Merrimack Pharmaceuticals Inc  (NASDAQ: MACK)


Merrimack Pharmaceuticals Inc's ROA from the first quarter of 2024 to the first quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Merrimack Pharmaceuticals Inc's ROA in the first quarter of 2024?
Merrimack Pharmaceuticals Inc achieved a return on average assets (ROA) of 265.28 % in its first quarter of 2024, this is above MACK's average return on assets of -9.7%.
Merrimack Pharmaceuticals Inc assets over the 12 months ending in its first quarter of 2024 are valued at $76 million

ROA has improved compared to -6.09% in the fourth quarter of 2023, due to net income growth.

However, within the Healthcare sector 3 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2024 quarter, so far to 25, from total ROA ranking in the fourth quarter of 2023 at 3770.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter
Y / Y Total Assets Change 1144.32 % -3.27 % 41.52 % 38.37 % 34.13 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 200 -1 -1 -2 -2
Return On Assets (TTM) 265.28 % -6.09 % -7.33 % -8.8 % -10.02 %
MACK's Total Ranking # 25 # 3770 # 3417 # 3552 # 3739
Total Assets (TTM) in million 244 19 19 19 20
Seq. Total Assets Change 1173.31 % -0.58 % -0.77 % -0.95 % -1.01 %
Seq. Net Income Change - - - - -

MACK's 5 Years Annual ROA >> Back to MACK Management Effectiveness >> Compare MACK ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 2
Sector # 4
Overall # 25

Return On Assets Statistics
High Average Low
345.89 %
-9.7 %
-138.59 %
(Jun 30 2017)   (Mar 31 2017)





Financial Statements
Merrimack Pharmaceuticals Inc's Assets $ 244 million MACK's Balance sheet
Merrimack Pharmaceuticals Inc's Income $ 201 million Quarterly MACK's Income Statement
MACK's Income by Division See MACK's Income by Division



Annual Return On Assets (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019
Y / Y Total Assets Change -3.27 % 34.49 % -12.08 % -16.46 % -77.32 %
Total Assets in million 19 20 15 17 20
Y / Y Net Income Change - - - - -
Net Income in million -1 -2 0 -3 -17
Annual Return On Assets -6.15 % -7.78 % 0 % -18.05 % -86.31 %

MACK's 5 Years Annual ROA >> Back to MACK Management Effectiveness >> Compare MACK ROA to its Competitors



More Return On Assets Ratios
MACK's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MACK's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MACK's Competitors
Subscribers only: Roa for Merrimack Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for MACK's Customers

You may also want to know
MACK's Roi MACK's Inventory Turnover Ratio MACK's Growth Rates MACK's Dividend Comparisons
MACK's Profitability Ratios MACK's Asset Turnover Ratio MACK's Dividend Growth
MACK's Roe MACK's Valuation Ratios MACK's Financial Strength Ratios MACK's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2024, within Healthcare Sector ROA
Evofem Biosciences Inc   411.49 %
Odyssey Health Inc   291.92 %
Ir med Inc   282.34 %
Merrimack Pharmaceuticals Inc  265.28 %
Kaya Holdings Inc   213.11 %
Northview Acquisition Corp  170.11 %
Glucotrack Inc   150.73 %
Longduoduo Co Ltd  94.18 %
Roivant Sciences Ltd   90.33 %
Welsis Corp.  85.65 %
Entera Bio Ltd   85.01 %
Scynexis Inc   73.68 %
Biomx Inc  57.81 %
Ladrx Corporation  57.41 %

Date modified: 2026-09-12T06:14:30+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.